SPRUSON & FERGUSON
INTELLECTUAL PROPERTY

16 July 2015

The Registry of Patents
Intellectual Property Office of Singapore

Spruson & Ferguson (Asia) Pte Ltd
Reg. No. 200100515C

152 Beach Road
#37-05/06 Gateway East
Singapore 189721

Phone: +65 6333 7200
Fax: +65 6333 7222

mail.asia@spruson.com
www.spruson.com

Our Reference : 330SG468/KJR/GWH
Your Reference : 11201500288Q

Dear Sirs,

Singapore Patent Application No. 11201500288Q
Invention : Inhibitors Of Alpha-Crystallin Aggregation For The Treatment For Cataract
Applicant : Regents of The University of Michigan

We enclose the following documents to effect correction of the present application:

1. CM4; and
2. A copy of corrected description pages 3 and 12; and
3. A copy of corrected claims page 35.

Basis for Corrections

"5-cholestin-3b,25-diol"

"5-cholestin-3b,25-diol" formerly referenced on pages 3, 12 and 35 is a typographical error and has been corrected to reference "5-cholest**e**n-3b,25-diol" instead. It is evident that "5-cholestin-3b,25-diol" is a typographical error as the structural depiction of this compound that immediately precedes reference to "5-cholestin-3b,25-diol" has a cholest**e**n core structure:



(II)

Additionally, the correct term "5-cholest**e**n-3b,25-diol" is recited throughout the specification, for example, in paragraphs [0066], [0067], [0070], [0071], Table 2 etc.

It would therefore have been immediately obvious to the person skilled in the art that formerly referenced "5-cholestin-3b,25-diol" is a typographical error and should be corrected to reference "5-cholest**e**n-3b,25-diol" instead. It is clear that nothing else would have been intended other than what is offered as the correction.

Our Reference : 330SG468/KJR/GWH
Your Reference : 11201500288Q

We trust that the above is in order and we look forward to receiving a notification of allowance of the above corrections in due course.

Yours faithfully,

SPRUSON & FERGUSON (ASIA) PTE LTD